Aromatase inhibitors to augment height: Have we lost our inhibitions?

Pediatric Endocrinology Reviews

Volumn 5, Issue 3, 2008, Pages 756-759

  Geffner, Mitchell E ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Anastrazole; Aromatase inhibitor; Exemestane; Gonadotropin releasins hormone analog; Letrozole

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; GONADORELIN DERIVATIVE; GROWTH HORMONE; LETROZOLE; PLACEBO; PRASTERONE SULFATE; RECOMBINANT GROWTH HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE;

DELAYED PUBERTY; DRUG ABSORPTION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HORMONE RESISTANCE; HUMAN; OUTCOME ASSESSMENT; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; CHILD; MALE;

AROMATASE INHIBITORS; CHILD; GROWTH DISORDERS; HUMANS; MALE;

EID: 41549105826     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Carel JC. Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol Cell Endocrinol 2006;254-255:226-233
2. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler GB Jr. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908-917
3. van Gool SA, Kamp GA, Visser-van Balen H, Mul D, Waelkens JJ, Jansen M, Verhoeven-Wind L, Delemarre-van de Waal HA, de Muinck Keizer-Schrama SM, Leusink G, Roos JC, Wit JM. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab 2007;92:1402-1408
4. Tanaka T. Sufficiently long-term treatment with combined growth hormone and gonadotropin-releasing hormone analog can improve adult height in short children with isolated growth hormone deficiency (GHD) and in non-GHD short children. Pediatr Endocrinol Rev 2007;5:471-481
5. MacGillivray MH, Morishima A, Conte F, Grumbach M, Smith EP. Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor. Horm Res 1998;49(suppl 1):2-8
6. Conte FA, Grumbach MM, Ito Y, Fisher CR, Simpson ER. A syndrome of female pseudohermaphroditism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 1994;78:1287-1292
7. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-1061
8. Cernich J, Jacobson JD, Moore WV, Popovic J. Use of aromatase inhibitors in children with short stature. Pediatr Endocrinol Rev 2004;2:2-7
9. Damiani D, Damiani D. Pharmacological management of children with short stature: the role of aromatase inhibitors. J Pediatr (Rio) 2007;83(Suppl 5):S172-S177
10. Shulman DI, Francis GL, Palmert MR, Eugster EA. Use of aromatase inhibitors in pediatric endocrine patients. Pediatrics 2008 (in press)
11. Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol 2006;254-255:207-216
12. Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, Lippe B. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003;88:5951-5956
13. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743-1748
14. Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol 2006;64:510-513
15. Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab 2005;18:285-293
16. Mauras N, Welch S, Rini A, Klein KO. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 2004;17:1597-1606
17. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:6396-6402
18. Wickman S, Saukkonen T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol 2002;146:339-346
19. Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003;88:3785-3793
20. Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006;155:453-460
21. Mauras N, Bell J, Snow BG, Winslow KL. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertil Steril 2005;84:239-242
22. Wickman S, Dunkel L. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. J Clin Endocrinol Metab 2001;86:4887-4894
23. Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2005;19:2-24